Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
79 Resources Ltd
Advaxis, Inc. - Common Stock
Jaxon Mng Inc
Nicolet Bankshares Inc. - Common Stock
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lakefront Biotherapeutics - American Depositary Shares
(NQ:
LKFT
)
33.31
-0.08 (-0.24%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lakefront Biotherapeutics - American Depositary Shares
Lakefront Biotherapeutics Eyes 2027 Trials for Autoimmune Drug, Backed by €2.2 Billion in Cash
↗
Today 22:12 EST
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) is preparing to expand testing of its autoimmune drug candidate gamgertamig, with executives pointing to clinical data, potential...
Via
MarketBeat
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
↗
September 21, 2026
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of...
Via
MarketBeat
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
June 04, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
↗
May 23, 2026
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.
Via
The Motley Fool
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
↗
May 23, 2026
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.
Via
The Motley Fool
Topics
Artificial Intelligence
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1